Which benzodiazepine is safest in liver disease?
Which Benzodiazepine Is Safest in Liver Disease?
Benzodiazepines are among the drugs most likely to precipitate hepatic encephalopathy — yet they’re often unavoidable in alcohol withdrawal, acute agitation, or catatonia. In a patient with cirrhosis, the choice of agent is what makes them safe or dangerous. Here’s the rule.
The 30-second version
- Use the “LOT” benzodiazepines — lorazepam, oxazepam, temazepam. They’re cleared by glucuronidation (Phase II), which the failing liver preserves longer, and they have essentially no active metabolites to accumulate.
- Avoid diazepam and chlordiazepoxide. They’re oxidized (Phase I) — the pathway that fails first — and their long-acting active metabolites pile up and can tip a patient into encephalopathy.
- Lorazepam is the practical first choice — strongest evidence, and it comes IV, IM, and oral.
- Lowest dose, shortest course. Even the LOT agents can oversedate and precipitate HE in advanced disease.
- In alcohol withdrawal, use an LOT agent, CIWA-guided — and give thiamine before glucose.
Which benzodiazepines are safest in liver disease?
Lorazepam, oxazepam, and temazepam — the “LOT” agents — are the benzodiazepines of choice in liver disease.
They share one property that matters more than any other in a cirrhotic patient: they’re cleared by glucuronidation and carry essentially no active metabolites, so they don’t accumulate the way the oxidized benzodiazepines do.
| Agent | Metabolism | In liver disease |
|---|---|---|
| Lorazepam | Glucuronidation (Phase II) | Preferred — strongest evidence; IV/IM/PO |
| Oxazepam | Glucuronidation (Phase II) | Preferred — oral |
| Temazepam | Mainly glucuronidation (Phase II); minor demethylation to oxazepam | Preferred — oral; more of a hypnotic |
Why are the LOT benzodiazepines preferred?
Because glucuronidation — the Phase II pathway that clears them — is relatively preserved in liver disease, while the Phase I oxidation that clears the other benzodiazepines fails first.
The diseased liver loses its oxidative (CYP) capacity earlier and more severely than its conjugation capacity. Benzodiazepines that depend on oxidation are cleared slowly and generate long-acting active metabolites that build up over days; the glucuronidated agents largely sidestep both problems.
| Pathway | Benzodiazepines | Fate in liver disease |
|---|---|---|
| Phase II glucuronidation | Lorazepam, oxazepam, temazepam | Relatively preserved; essentially no active metabolites |
| Phase I oxidation (CYP) | Diazepam, chlordiazepoxide, and most others | Impaired early; active metabolites accumulate |
Which benzodiazepines should I avoid?
Avoid the oxidized, long-acting agents — diazepam and chlordiazepoxide above all — because their active metabolites accumulate and can precipitate hepatic encephalopathy.
| Agent | Problem in liver disease |
|---|---|
| Diazepam | Oxidized; long-acting active metabolite (desmethyldiazepam) accumulates → oversedation and HE risk |
| Chlordiazepoxide | Oxidized with active metabolites; same accumulation problem — a poor choice for withdrawal in cirrhosis |
| Alprazolam, clonazepam, midazolam | Also oxidized; not first-line — use with caution and only if an LOT agent won’t serve |
Which one should I actually reach for first?
Lorazepam.
It has the strongest evidence base in liver disease, predictable glucuronidation, and — uniquely useful — it’s available IV, IM, and oral, which covers withdrawal, acute agitation, and catatonia from the same molecule. Oxazepam and temazepam are sound alternatives; temazepam is oral-only and behaves more as a hypnotic than an all-purpose agent.
How should I dose it — and what’s the catch?
Lowest effective dose, shortest possible course — because even the LOT agents can oversedate and precipitate encephalopathy in advanced disease.
“Glucuronidation is preserved” is a relative statement, not a free pass. In Child-Pugh C disease, clearance of even the LOT agents slows, and every benzodiazepine remains a recognized precipitant of hepatic encephalopathy.
| Principle | Why it matters |
|---|---|
| Start low, go slow | Clearance is reduced even for glucuronidated agents in advanced disease |
| Shortest course | Benzodiazepines are named precipitants of hepatic encephalopathy |
| Watch for new confusion | Distinguish oversedation or emerging HE from the problem you’re treating |
| Relative, not absolute, safety | The LOT advantage narrows in Child-Pugh C — don’t treat it as risk-free |
What about alcohol withdrawal in a patient with cirrhosis?
Use an LOT agent — lorazepam — symptom-triggered or CIWA-guided, and give parenteral thiamine before glucose.
| Step | Detail |
|---|---|
| Benzodiazepine | Lorazepam (LOT), symptom-triggered / CIWA-guided, at the lowest total exposure |
| Thiamine | Parenteral, before glucose — glucose can precipitate Wernicke’s in a thiamine-deplete patient |
| Watch | Don’t mistake emerging hepatic encephalopathy for under-treated withdrawal, or vice versa |
What about Z-drugs and other sleep aids?
Most sedative-hypnotics need dose reduction and are not recommended in severe (Child-Pugh C) disease.
| Agent | In liver disease |
|---|---|
| Zolpidem | 5 mg IR / 6.25 mg ER / 1.75 mg low-dose SL in mild–moderate; avoid in severe |
| Zaleplon | 5 mg in mild–moderate; not recommended in severe |
| Eszopiclone | Maximum 2 mg in severe impairment |
| Ramelteon | Caution in mild–moderate (~4× / ~10× exposure); not recommended in severe |
| Lemborexant | Maximum 5 mg in moderate; not recommended in severe |
Read the full chapter — free
The LOT rule, alcohol-withdrawal dosing, and the full sedative-hypnotic table live in Benzodiazepines & the LOT Rule — a free chapter from Psychopharmacology with Hepatic Impairment. No membership required.
Read the free chapter →The full course — 12 chapters
Foundations
The Hepatic Decision FrameworkFreeValproate: The Critical Drug
Valproate HepatotoxicityMembers Valproate-Induced Hyperammonemic EncephalopathyMembersDosing by Drug Class
Antidepressants in Hepatic ImpairmentMembers Antipsychotics in Hepatic ImpairmentMembers Mood Stabilizers Beyond ValproateMembers Benzodiazepines & Sedative-Hypnotics — the LOT RuleFree Stimulants & ADHD MedicationsMembersHigh-Risk Decisions
Drug-Precipitated Hepatic EncephalopathyMembers The Hepatotoxic WatchlistMembers Alcohol-Associated Liver Disease, Cirrhosis & the Transplant PatientMembersQuick Reference
Hepatic Quick-Reference Dosing TableMembersPsychopharmacology in Medical Conditions:
Rapid Decision Guide
Medication Safety in Medical Conditions
Quick-reference safety guidance for prescribing psychotropic medications in patients with renal, hepatic, cardiac, and other medical comorbidities.
Psychotropics & Cardiac Safety (QTc)
Quickly check QTc risk and cardiac safety across psychotropics with clear, tiered guidance.
View Guide →Psychotropics in Renal Impairment
Dose-by-eGFR guidance across drug classes — including lithium and dialysis.
View Guide →Psychotropics in Hepatic Impairment
Child-Pugh–based dosing, hepatotoxic agents to avoid, and the encephalopathy traps.
View Guide →Psychotropics in Seizure Disorders
Seizure-threshold risk, psychotropic–antiepileptic interactions, and safe agent selection.
Releasing SoonPsychotropics in HIV/AIDS
Antiretroviral interactions (ritonavir/cobicistat CYP) and neuropsychiatric effects of ART.
Releasing SoonPsychotropics in Organ Transplant
Immunosuppressant interactions (tacrolimus/cyclosporine, CYP3A4) and QTc overlap.
Releasing SoonPsychotropics in Pulmonary Disease
Benzodiazepine respiratory risk in COPD and smoking-cessation CYP1A2 shifts (clozapine/olanzapine).
Releasing SoonFull Access Available to Academy Members
This clinical series is part of the Psychiatry Education Forum Academy and is available exclusively to enrolled members.
Designed for busy clinicians, the Academy provides structured, high-yield, point-of-care content across psychopharmacology — so you can make faster, more confident decisions in real-world practice.
If you're looking for rapid medication-level guidance, standardized frameworks, and clinic-ready tools you can actually use during patient care, this is built for you.
Join the Academy to unlock full access to this and our 500+ clinically relevant chapters.
Yearly Plan
- Best value
- Maximum savings
- For committed learners
- Most popular
Discounts available for: Residents & Students only.
Email your student information (program details and confirmation of student status) to:
[email protected]
Educational content only. Dosing reflects current FDA labeling and primary literature at the time of writing; it supports, and does not replace, individual clinical judgment and current prescribing information. Verify against the current label before prescribing.
Responses